The Claim

Tirzepatide reduces serum uric acid levels to a degree that is comparable to the reduction achieved by low-dose allopurinol in obese patients.

Source: Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
36score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

Tirzepatide lowers uric acid in the blood by the same amount as low-dose allopurinol in people with obesity.

See the scientific wording

Tirzepatide’s reduction in serum uric acid is comparable in magnitude to the effects of low-dose allopurinol, suggesting it may serve as a pharmacological alternative for uric acid management in obese patients.

Why this might work

Losing weight decreases fat tissue, which lowers the amount of uric acid made by the body and helps the kidneys remove more uric acid from the blood.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.

    Tirzepatide, a weight-loss drug, lowered uric acid levels in obese patients by almost 1 point — similar to how a low dose of the gout medicine allopurinol works. This suggests it might help obese people manage uric acid without needing a separate gout drug.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.